News
RCDTF
49.00
NaN%
--
Recordati Executes Treasury Share Sales Under Stock Option Plans
TipRanks · 3d ago
Recordati Industria Chimica e Farmaceutica SPA (0KBS) Gets a Hold from Kepler Capital
TipRanks · 11/14 01:47
Recordati Reports Strong Growth and Doubles Isturisa® Sales Estimates
TipRanks · 11/11 19:33
Recordati Completes Share Buyback Program to Support Management Incentive Plans
TipRanks · 10/27 19:42
Recordati Industria Chimica e Farmaceutica SPA (0KBS) Gets a Hold from Kepler Capital
TipRanks · 10/25 01:49
Recordati Appoints Mike McClellan as New CFO
TipRanks · 10/23 09:43
Recordati Updates on Share Buyback Program Execution
TipRanks · 10/21 17:14
Recordati Industria Chimica e Farmaceutica SPA (0KBS) Gets a Sell from Barclays
TipRanks · 10/21 11:55
Recordati Updates on Share Buyback Program Execution
Barchart · 10/15 13:06
Recordati Updates on Share Buyback Program Execution
Barchart · 10/09 12:00
Recordati Updates on Share Buyback Program Execution
TipRanks · 10/01 16:23
Recordati Updates on Share Buyback Program
TipRanks · 09/23 17:03
Recordati Announces CFO Resignation and Board Changes
TipRanks · 09/18 16:26
Recordati Updates on Share Buyback Program
TipRanks · 09/17 17:06
Weekly Report: what happened at RCDTF last week (0908-0912)?
Weekly Report · 09/15 11:26
Recordati Updates on Share Buyback Program Execution
TipRanks · 09/10 16:53
Weekly Report: what happened at RCDTF last week (0901-0905)?
Weekly Report · 09/08 11:29
Recordati Updates on Share Buyback Program Execution
TipRanks · 09/03 16:52
More
Webull provides a variety of real-time RCDTF stock news. You can receive the latest news about Recordati Industria Chimica Ef through multiple platforms. This information may help you make smarter investment decisions.
About RCDTF
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.